Evaluation of Autologous CAR T Cells (Tarcidomgen Kimleucel) in Refractory and Relapsed CD19+ B Cell Neoplasms

The primary objective of this study is to evaluate the efficacy of **autologous CAR T cells (Tarcidomgen Kimleucel)** in the treatment of refractory and relapsed **CD19+ B cell neoplasms**. This is clinically relevant as these neoplasms often exhibit resistance to conventional therapies, and the use of CAR T cells represents a novel therapeutic approach that may improve patient outcomes by targeting and eliminating malignant B cells expressing the CD19 antigen.

The clinical trial involves the application of autologous **CAR T cells** (Tarcidomgen Kimleucel) for the treatment of refractory and relapsed CD19+ B cell neoplasms. The study population includes both male and female participants, with an age range of 18 to 65 years. Participants are not considered part of a vulnerable population. The sponsor has not provided information regarding the total number of participants. The trial population was selected based on specific criteria, although these criteria have not been disclosed. Participants' general health status, lifestyle considerations such as diet, physical activity, and habits have not been detailed in the available data.

The clinical trial is designed to evaluate the efficacy and safety of **autologous CAR T cells** (Tarcidomgen Kimleucel) in the treatment of refractory and relapsed CD19+ B cell neoplasms. This trial is structured as a Phase 1 study, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The trial is expected to commence recruitment on June 2, 2023, and is projected to conclude by December 31, 2025. Participants will be involved in the study for the duration of the trial, with specific timelines for individual involvement determined by the study protocol.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful inclusion, participants will undergo a series of follow-up visits at regular intervals to monitor their response to the treatment and to ensure their safety. These visits will include comprehensive assessments, such as physical examinations, laboratory tests, and imaging studies, as required by the study protocol. The end-of-study visit will mark the conclusion of a participant's involvement, during which final evaluations will be conducted to gather data on the long-term effects of the treatment.

Participants are expected to remain in the study for its entire duration unless specific conditions necessitate early termination. Such conditions may include adverse reactions to the treatment, withdrawal of consent, or any other medical or ethical considerations that may arise during the trial. The study is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of June 2, 2023, and an estimated end date of December 31, 2025. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a systematic approach to collect and analyze data, ensuring that the results are scientifically valid and reliable. The focus will be on gathering comprehensive data throughout the trial duration to evaluate the treatment's impact effectively.